Price targets raised to the $430 to $450 range. It was an outstanding report. AVGO will be back over $400 in a week or so.AVGO getting hammered today so far
Agreed - this selloff is absurd unless you believe there are 'big money' reasons to "tank it" for a quick money grab on the short play or a reset going into next year. The earnings report was outstanding and this thing will be up near $500 next year. .Price targets raised to the $430 to $450 range. It was an outstanding report. AVGO will be back over $400 in a week or so.
Another rug pull on legalization or rescheduling or is this one finally real? If real, TLRY et al have a lot of room to run.Cannabis stocks jumping. I wish I had bought back TLRY after I sold it last month
Actually, nothing real. A fake report of an FDA denial was posted on a Yahoo Finance page. It triggered automated selling, but then everyone figured out the info was BS. The stock gained most of the dump back.I was out of the loop most of today traveling what happened with MIST? Looks like my stop loss triggered.
Approved!!!Actually, nothing real. A fake report of an FDA denial was posted on a Yahoo Finance page. It triggered automated selling, but then everyone figured out the info was BS. The stock gained most of the dump back.
FDA news should post sometime on Monday.
AMEN! This is going to be interesting on Monday and over the next few weeks. Cardamyst was approved for PSVT which is a relatively smaller patient population. However, the next indication they are working on is A-FIB, which is huge. Getting PSVT approved will now give the street much more confidence that A-FIB is within reach and likely cause a re-rating of the stock.Approved!!!
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | Milestone Pharmaceuticals, Inc.
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT enables development of AFib-RVR under sNDA pathway Milestone well-capitalized to launch andinvestors.milestonepharma.com
Whoever posted it should go to prison it triggered my stop loss. Hello SEC?!?Actually, nothing real. A fake report of an FDA denial was posted on a Yahoo Finance page. It triggered automated selling, but then everyone figured out the info was BS. The stock gained most of the dump back.
FDA news should post sometime on Monday.
+1Whoever posted it should go to prison it triggered my stop loss. Hello SEC?!?
Any thoughts on $SLS?My biotech home run swings are:
1. MIST - approval decision will be announced on Friday or Monday. This is an all or nothing play.
2. PRME - very early clinical-stage biotech, but I love its science and believe they will be successful. Watch and slowly buy during dips.
3. Love Insmed.....very good company. They only have one main product, but good pipeline.
4. Ascendis - growing sales with already 3 products approved in the US.
5. Madrigal - NASH/MASH is a great space to be in (adjacent to obesity/GLP-1s).
Many other good ones to chat about, but this is my list for now.
Not too much right now on SLS, need to research more. Based on what I know, the AML space is very crowded, but if you can show legit improvement, the market is huge and lucrative (so high risk, high reward). Also, it seems like they will need to raise again in early/mid-2026, so perhaps wait for the dilution dip to buy (or add)?Any thoughts on $SLS?
It's all about that Beta.Junior copper miners? Young man, you have a problem.
Then again, I'm waiting for the FDA decision today or Monday on MIST, so we all have our burden to bear.
My new GLD futures already blowing up!
AVGO = price targets are increasing, major intraday turnaround?
Sold next Friday Calls. $21 strike.RIVN being very cool, up 15% today. Touched $19, 52 week high.
Autonomous.Maybe the reason?
Needham Maintains Buy on Rivian Automotive, Raises Price Target to $23
I was able to get in on TLRY at $12.2.....should have bought calls instead.I see cannabis stocks are still rolling. I should buy more tomorrow.